Cardiovascular morbidity in patients after treatment for testicular cancer

Czech version

Authors: M. Valentová; B. Mladosievičová
Authors‘ workplace: Oddelenie klinickej patofyziológie Lekárskej fakulty UK Bratislava, Slovenská republika, prednosta doc. MU Dr. Marián Bernadič, CSc., mim. prof.
Published in: Vnitř Lék 2010; 56(9): 915-919
Category: Reviews

Overview

Increase of incidence and favorable prognosis of testicular cancer are accompanied by growing evidence of late complications following antineoplastic treatment, such as cardiovascular diseases, peripheral neuropathy, renal damage, hearing impairment, secondary malignancies, pulmonary toxicity, gonadal dysfunction and bone mineral density abnormalities. During the last years a sufficient evidence has been accumulated that there is a higher incidence of cardiovascular diseases, particularly in patients treated with high‑dose cisplatin chemotherapy or mediastinal irradiation. Acute myocardial infarction and angina pectoris are the most common from cardiovascular complications. Several authors have reported high prevalence of hypertension, dyslipidemia, metabolic syndrome, endothelial dysfunction and also an excessive increase of body mass index among patients being treated successfully for testicular cancer. Pathogenesis of the cardiovascular toxicity remains still unclear. At present there are no clear and widely accepted recommendations on follow‑up management including late complications of treatment for testicular cancer. Early identification of cardiovascular risk factors and their treatment may improve quality and expectancy of their life.

Key words:
testicular cancer – late effects – cardiovascular morbidity

Sources

1. Ondruš D, Ondrušová M. Nádory testis – diagnostika a liečba. Onkológia 2008; 3: 170– 174.

2. Safaei Diba C, Pleško I. Cancer incidence in the Slovak Republic 2004. National Cancer Registry of the Slovak Republic. Bratislava: National Health Information Center 2008.

3. Ondrusova M, Ondrus D, Dusek L et al. Damage of hormonal function and bone metabolism in long‑term survivors of testicular cancer. Neoplasma 2009; 56: 473– 479.

4. Strumberg D, Brügge S, Korn MW et al. Evaluation of long‑term toxicity in patients after cisplatin‑based chemotherapy for non‑seminomatous testicular cancer. Ann Oncol 2002; 13: 229– 236.

5. Kollmannsberger C, Kuzcyk M, Mayer F et al. Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 1999; 17: 275– 281.

6. Fosså SD, Aass N, Harvei S et al. Increased mortality rates in young and middle‑ aged patients with malignant germ cell tumours. Br J Cancer 2004; 90: 607– 612.

7. van den Belt‑ Dusebout AW, Nuver J, de Wit R et al. Long‑term risk of cardiovascular disease in 5‑year survivors of testicular cancer. J Clin Oncol 2006; 24: 467– 475.

8. Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a long‑term complication of treatment for testicular cancer. J Clin Oncol 2003; 21: 1513– 1523.

9. Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long‑term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725– 1732.

10. Zagars GK, Ballo MT, Lee AK et al. Mortality after cure of testicular seminoma. J Clin Oncol 2004; 22: 640– 647.

11. Lederman GS, Sheldon TA, Chaffey JT et al. Cardiac disease after mediastinal irradiation for seminoma. Cancer 1987; 60: 772– 776.

12. Cuzick J, Stewart H, Rutqvist L et al. Cause- specific mortality in long‑term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994; 12: 447– 453.

13. Rutqvist LE, Lax I, Fornander T et al. Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys 1992; 22: 887– 896.

14. Boivin JF, Hutchison GB, Lubin JH et al. Coronary artery disease mortality in patients treated for Hodgkin’s disease. Cancer 1992; 69: 1241– 1247.

15. Glanzmann C, Kaufmann P, Jenni R et al. Cardiac risk after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol 1998; 46: 51– 62.

16. Corn BW, Trock BJ, Goodman RL. Irradiation‑related ischemic heart disease. J Clin Oncol 1990; 8: 741– 750.

17. Cassady JR. Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys 1995; 31: 1249– 1256.

18. Kim TH, Somerville PJ, Freeman CR. Unilateral radiation nephropathy: the long‑term significance. Int J Radiat Oncol Biol Phys 1984; 10: 2053– 2059.

19. Dewit L, Anninga JK, Hoefnagel CA et al. Radiation injury in the human kidney: a prospective analysis using specific scintigraphic and biochemical endpoints. Int J Radiat Oncol Biol Phys 1990; 19: 977– 983.

20. Urbanová D, Mladosievičová B. Kardiotoxicita antracyklínovej liečby vo svetle nových biochemických diagnostických možností. Vnitř Lék 2007; 53: 669– 677.

21. Sagstuen H, Aass N, Fosså SD et al. Blood pressure and body mass index in long‑term survivors of testicular cancer. J Clin Oncol 2005; 23: 4980– 4990.

22. Nord C, Fosså SD, Egeland T. Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. Br J Cancer 2003; 88: 36– 41.

23. Raghavan D, Cox K, Childs A et al. Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 1992; 10: 1386– 1389.

24. Petersen PM, Hansen SW. The course of long‑term toxicity in patients treated with cisplatin‑based chemotherapy for non‑seminomatous germ‑ cell cancer. Ann Oncol 1999; 10: 1475– 1483.

25. Haugnes HS, Aass N, Fosså SD et al. Components of the metabolic syndrome in long‑term survivors of testicular cancer. Ann Oncol 2007; 18: 241– 248.

26. Nuver J, Smit AJ, Wolffenbuttel BH et al. The metabolic syndrome and disturbances in hormone levels in long‑term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23: 3718– 3725.

27. Oh JH, Baum DD, Pham S et al. Long‑term complications of platinum‑based chemotherapy in testicular cancer survivors. Med Oncol 2007; 24: 175– 181.

28. Levy D, Ehret GB, Rice K et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009. Epub ahead of print.

29. Lindgren CM, Heid IM, Randall JC et al. Genome- wide association scan meta‑analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet 2009; 5: e1000508.

30. Kolz M, Johnson T, Sanna S et al. Meta‑analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009; 5: e1000504.

31. Wallace C, Newhouse SJ, Braund P et al. Genome‑ wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet 2008; 82: 139– 149.

32. Boyer M, Raghavan D, Harris PJ et al. Lack of late toxicity in patients treated with cisplatin‑containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 1990; 8: 21– 26.

33. Fenton DW, Verma S, Venner P et al. The lack of long‑term effect of Cisplatin based combination chemotherapy on serum cholesterol for treatment of testicular cancer. J Urol 2002; 168: 1971– 1974.

34. Ellis PA, Fitzharris BM, George PM et al. Fasting plasma lipid measurements following cisplatin chemotherapy in patients with germ cell tumors. J Clin Oncol 1992; 10: 1609– 1614.

35. Shi Y, Inoue S, Shinozaki R et al. Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro. Jpn J Cancer Res 1998; 89: 757– 767.

36. Nuver J, De Haas EC, Van Zweeden M et al. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 2010; 23: 247– 253.

37. Gietema JA, Meinardi MT, Messerschmidt J et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000; 355: 1075– 1076.

38. Nuver J, Smit AJ, Sleijfer DT et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long‑term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40: 701– 706.

39. Vaughn DJ, Palmer SC, Carver JR et al. Cardiovascular risk in long‑term survivors of testicular cancer. Cancer 2008; 112: 1949– 1953.

40. Fosså SD, Aass N, Winderen M et al. Long‑term renal function after treatment for malignant germ‑ cell tumours. Ann Oncol 2002; 13: 222– 228.

41. Barbagallo M, Dominguez LJ, Galioto A et al. Role of magnesium in insulin action, diabetes and cardio‑ metabolic syndrome X. Mol Aspects Med 2003; 24: 39– 52.

42. Phillips GB, Jing T, Heymsfield SB. Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction. Metabolism 2003; 6: 784– 790.

43. van den Beld AW, Bots ML, Janssen JA et al. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 2003; 1: 25– 31.

44. Yang XC, Jing TY, Resnick LM et al. Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men. Arterioscler Thromb 1993; 4: 467– 471.

45. Haffner SM, Valdez RA, Mykkänen L et al. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 1994; 5: 599– 603.

46. Simon D, Preziosi P, Barrett‑ Connor E et al. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia 1992; 2: 173– 177.

47. Nord C, Bjøro T, Ellingsen D et al. Gonadal hormones in long‑term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 2003; 44: 322– 328.

48. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008; 53: 497– 513.